Akeso's Cadonilimab Enters Crucial Phase III for Early Colon Cancer
Context mode is active. Hover over any highlighted term to see its definition. Click a nested term to go deeper.
Akeso, Inc. (9926.HK) has just started a crucial Phase III clinical study for its innovative Cadonilimab (AK104) in patients with resectable MSI-H or dMMR colon cancer, marking a significant step towards a potential new curative treatment. The first patient has been dosed in this perioperative trial, aiming to establish Cadonilimab as a monotherapy for a challenging subset of colon cancer. This move extends the bispecific antibody reach beyond its current approvals in advanced cervical and gastric cancers, signaling a shift towards earlier intervention for solid tumors. Currently, patients with MSI-H/dMMR colon cancer see limited benefit from standard chemotherapy, with pathological response rates hovering around a dismal 7%. While immune checkpoint inhibitors are already a go-to for metastatic MSI-H/dMMR colorectal cancer, no immunotherapy has yet received approval for treating localized disease in the critical perioperative setting. Akeso is betting on Cadonilimab dual PD-1/CTLA-4 blockade to supercharge the immune system, building on promising Phase II data that showed an impressive 84.6% pathological complete response rate and 100% major pathological response rate in similar patients. The success of this Phase III study, known as COMPASSION-40/AK104-313, could reshape the treatment landscape for thousands of colon cancer patients worldwide, potentially offering a path to durable cure where options are currently scarce. Observers will be keenly watching for results that could validate the power of bispecific antibodies in earlier disease stages, further cementing immunotherapy's role as a foundational treatment in immuno-oncology 2.0. This trial is one of 13 Phase III studies ongoing for Cadonilimab across various cancers, underscoring Akeso's commitment to advancing innovative biological medicines.